Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Phathom Pharmaceuticals, Inc. (PHAT) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/21/2023 8-K Other Events  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
08/10/2023 8-K Quarterly results
Docs: "Phathom Pharmaceuticals Reports Second Quarter 2023 Results"
08/10/2023 10-Q Quarterly Report for the period ended June 30, 2023
07/21/2023 4/A Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]
07/17/2023 4 Henderson Molly (CFO and CBO) has filed a Form 4 on Phathom Pharmaceuticals, Inc.
Txns: Granted 25,000 shares @ $1, valued at $25k
07/17/2023 4 Curran Terrie (President and Chief Executive) has filed a Form 4 on Phathom Pharmaceuticals, Inc.
Txns: Granted 200,000 shares @ $0
Disposed/sold 175,000 options @ $32.2, valued at $5.6M
Disposed/sold 225,000 options @ $39.11, valued at $8.8M
07/17/2023 4 Nabulsi Azmi (COO) has filed a Form 4 on Phathom Pharmaceuticals, Inc.
Txns: Granted 110,000 shares @ $0
Disposed/sold 70,000 options @ $32.2, valued at $2.3M
Disposed/sold 150,000 options @ $39.11, valued at $5.9M
07/17/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
07/17/2023 SC TO-I/A Form SC TO-I/A - Tender offer statement by Issuer: [Amend]
06/12/2023 8-K Other Events  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
06/05/2023 4 Parikh Asit (Director) has filed a Form 4 on Phathom Pharmaceuticals, Inc.
Txns: Granted 15,000 shares @ $7.4, valued at $111k
Disposed/sold 15,000 options to buy @ $7.4, valued at $111k
06/05/2023 4 Henderson Molly (CFO and CBO) has filed a Form 4 on Phathom Pharmaceuticals, Inc.
Txns: Sold 1,960 shares @ $11.4121, valued at $22.4k
05/30/2023 4 Topper James N (10% Owner) has filed a Form 4 on Phathom Pharmaceuticals, Inc.
Txns: Granted 9,000 shares @ $0
Granted 15,000 options to buy @ $11.72, valued at $175.8k
05/30/2023 4 Stenhouse Mark (Director) has filed a Form 4 on Phathom Pharmaceuticals, Inc.
Txns: Granted 9,000 shares @ $0
Granted 15,000 options to buy @ $11.72, valued at $175.8k
05/30/2023 4 Socks David A (Director) has filed a Form 4 on Phathom Pharmaceuticals, Inc.
Txns: Granted 9,000 shares @ $0
Granted 15,000 options to buy @ $11.72, valued at $175.8k
05/30/2023 4 Parikh Asit (Director) has filed a Form 4 on Phathom Pharmaceuticals, Inc.
Txns: Granted 9,000 shares @ $0
Granted 15,000 options to buy @ $11.72, valued at $175.8k
05/30/2023 4 FIELDS HEIDI (Director) has filed a Form 4 on Phathom Pharmaceuticals, Inc.
Txns: Granted 9,000 shares @ $0
Granted 15,000 options to buy @ $11.72, valued at $175.8k
05/30/2023 4 KARBE FRANK (Director) has filed a Form 4 on Phathom Pharmaceuticals, Inc.
Txns: Granted 9,000 shares @ $0
Granted 15,000 options to buy @ $11.72, valued at $175.8k
05/30/2023 4 COLA MICHAEL F (Director) has filed a Form 4 on Phathom Pharmaceuticals, Inc.
Txns: Granted 9,000 shares @ $0
Granted 15,000 options to buy @ $11.72, valued at $175.8k
05/30/2023 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders...
Docs: "Certificate of Amendment to Amended and Restated Certificate of Incorporation",
"Certificate of Amendment to Amended and Restated Certificate of Incorporation"
05/26/2023 SC 13D/A Frazier Life Sciences Public Fund, L.P. reports a 18.5% stake in Phathom Pharmaceuticals, Inc.
05/24/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Underwriting Agreement, by and among Phathom Pharmaceuticals, Inc. and Jefferies LLC and Evercore Group L.L.C., as representatives of the several underwriters named therein",
"Opinion of Latham & Watkins LLP",
"Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock Florham Park, N.J., May 23, 2023 - Phathom Pharmaceuticals, Inc. , a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. In addition, Phathom intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the total number of the shares of its common stock offered in the public offering. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Phathom intends to use the net proceeds from the proposed offer...",
"Phathom Pharmaceuticals Announces Pricing of Public Offering of Common Stock Florham Park, N.J., May 23, 2023 - Phathom Pharmaceuticals, Inc. , a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today the pricing of its underwritten public offering of 11,125,000 shares of its common stock at a price to the public of $11.75 per share. The gross proceeds to Phathom from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be approximately $130.7 million. In addition, Phathom has granted the underwriters a 30-day option to purchase up to an additional 1,668,750 shares of common stock at the public offering price, less underwriting discounts and commiss..."
05/24/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
05/23/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
05/23/2023 8-K Other Events  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
05/23/2023 4 Henderson Molly (CFO and CBO) has filed a Form 4 on Phathom Pharmaceuticals, Inc.
Txns: Sold 2,110 shares @ $12.8744, valued at $27.2k
05/10/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/10/2023 8-K Quarterly results
Docs: "Phathom Pharmaceuticals Reports First Quarter 2023 Results"
05/05/2023 SC 13D/A Frazier Life Sciences Public Fund, L.P. reports a 19.3% stake in Phathom Pharmaceuticals, Inc.
04/13/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/13/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/13/2023 ARS Form ARS - Annual Report to Security Holders:
04/04/2023 8-K Other Events  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
03/31/2023 PRE 14A Form PRE 14A - Other preliminary proxy statements:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy